Affymetrix (Santa Clara, California) Exclusively Licenses Technology From Peptide Groove LLP For HLA Typing From Genotyping Data

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (NASDAQ:AFFX) announced today that it has exclusively licensed technology from Peptide Groove LLP that enables HLA typing of human samples from genotyping data generated from a variety of assays including the company's Axiom® genotyping assays. The partners at Peptide Groove LLP developed HLA*IMP, the first HLA typing statistical imputation method which can call 4-digit HLA types from SNP genotyping data with high accuracy. Conventional methods for HLA typing, such as DNA sequencing, can be laborious, time consuming, and expensive. Imputing HLA types from genotyping data, such as those from Affymetrix’ Axiom genotyping platform, offers a new, very high-throughput, and low-cost approach.

Help employers find you! Check out all the jobs and post your resume.